Published in Antimicrob Agents Chemother on September 01, 1977
The life and times of the Enterococcus. Clin Microbiol Rev (1990) 16.58
Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest (1983) 5.59
Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin Microbiol Rev (1990) 3.82
Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev (2003) 3.72
High-level, plasmid-borne resistance to gentamicin in Streptococcus faecalis subsp. zymogenes. Antimicrob Agents Chemother (1979) 3.42
Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother (1994) 3.02
Enterococci from Bangkok, Thailand, with high-level resistance to currently available aminoglycosides. Antimicrob Agents Chemother (1983) 2.88
Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis. J Clin Microbiol (1988) 2.59
Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism. J Clin Invest (1978) 2.48
Antibiotic combinations: should they be tested? Clin Microbiol Rev (1988) 2.34
High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis. J Clin Microbiol (1988) 2.11
Broad geographical distribution of homologous erythromycin, kanamycin, and streptomycin resistance determinants among group D streptococci of human and animal origin. Antimicrob Agents Chemother (1986) 2.07
Plasmid-mediated resistance to antibiotic synergism in enterococci. J Clin Invest (1978) 1.90
Susceptibility of enterococci to trimethoprim and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother (1985) 1.73
Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J Clin Microbiol (1988) 1.58
High-level aminoglycoside resistance in group A, B, G, D (Streptococcus bovis), and viridans streptococci. Antimicrob Agents Chemother (1982) 1.47
Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother (1984) 1.45
Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob Agents Chemother (1990) 1.38
Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance. Antimicrob Agents Chemother (1991) 1.35
Comparison of the new MicroScan Pos MIC Type 6 panel and AMS-Vitek Gram Positive Susceptibility Card (GPS-TA) for detection of high-level aminoglycoside resistance in Enterococcus species. J Clin Microbiol (1991) 1.30
Evaluation of a commercial microtiter system (MicroScan) using both frozen and freeze-dried panels for detection of high-level aminoglycoside resistance in Enterococcus spp. J Clin Microbiol (1990) 1.27
Antimicrobial resistance among enterococci. Antimicrob Agents Chemother (1991) 1.25
Methodological variation in antibiotic synergy tests against enterococci. J Clin Microbiol (1981) 1.18
Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob Agents Chemother (1992) 1.18
Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis. Antimicrob Agents Chemother (1985) 1.16
Resistance to antibiotic synergism in Streptococcus faecalis: further studies with amikacin and with a new amikacin derivative, 4'-deoxy, 6'-N-methylamikacin. Antimicrob Agents Chemother (1981) 1.16
Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s. Epidemiol Infect (1989) 1.05
False susceptibility of enterococci to aminoglycosides with blood-enriched Mueller-Hinton agar for disk susceptibility testing. J Clin Microbiol (1985) 0.98
Pathogenicity of the enterococcus in surgical infections. Ann Surg (1990) 0.88
Antibiotic prophylaxis against streptomycin-resistant and -susceptible Streptococcus faecalis endocarditis in rabbits. Antimicrob Agents Chemother (1983) 0.77
Action and interaction of penicillin and gentamicin on enterococci. J Clin Pathol (1979) 0.77
The ineffectiveness of tobramycin combination therapy in Streptococcus faecium endocarditis. Yale J Biol Med (1984) 0.75
Recognition of group D streptococcal species of human origin by biochemical and physiological tests. Appl Microbiol (1972) 13.09
Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro, with special reference to species differences. Am J Med Sci (1969) 10.08
Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med (1971) 6.08
Antibiotic synergism of enterococci. Relation to inhibitory concentrations. Arch Intern Med (1970) 5.73
Identification of streptococci: use of lysozyme and Streptomyces albus filtrate in the preparation of extracts for Lancefield grouping. J Clin Microbiol (1975) 3.53
Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin. Antimicrob Agents Chemother (1973) 2.83
Penicillin-streptomycin treatment of enterococcal endocarditis. A re-evaluation. N Engl J Med (1966) 1.76
Effects of ampicillin-amikacin and ampicillin-rifampin on enterococci. Antimicrob Agents Chemother (1976) 1.71
Antibiotic synergism against group D streptococci in the treatment of endocarditis. Med J Aust (1973) 1.53
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1985) 7.83
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med (1971) 6.08
Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 5.90
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother (1990) 5.81
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1986) 5.30
Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature (1990) 5.20
Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis (1979) 4.70
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med (1990) 4.40
Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med (1974) 4.10
How far to go with Enterobacteriaceae? J Infect Dis (1969) 4.10
Antimicrobial-drug resistance. N Engl J Med (1996) 4.07
Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) (1977) 4.05
Biochemical differentiation of the Enterobacteriaceae with the aid of lysine-iron-agar. Appl Microbiol (1966) 3.96
In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother (1982) 3.95
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother (1988) 3.80
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother (1993) 3.80
Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol (1971) 3.59
Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med (1980) 3.59
Amebiasis: epidemiologic studies in the United States, 1971-1974. Ann Intern Med (1978) 3.58
Synergy of penicillin and gentamicin against Enterococci. J Infect Dis (1971) 3.55
Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrob Agents Chemother (1980) 3.54
Identification of streptococci: use of lysozyme and Streptomyces albus filtrate in the preparation of extracts for Lancefield grouping. J Clin Microbiol (1975) 3.53
Extrarespiratory streptococcal infections. Importance of the various serologic groups. N Engl J Med (1966) 3.50
Current concepts in parasitology. Amebiasis. N Engl J Med (1978) 3.41
Nonfermentative gram-negative bacilli of nosocomial interest. Am J Med (1970) 3.08
Penicillin and gentamicin therapy for enterococcal infections. JAMA (1973) 3.07
Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother (1991) 3.00
Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet (1975) 3.00
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother (1983) 2.99
Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1981) 2.88
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother (1988) 2.83
Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin. Antimicrob Agents Chemother (1973) 2.83
Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother (1982) 2.68
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother (1988) 2.59
The enterococcus: "putting the bug in our ears". Ann Intern Med (1987) 2.59
A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother (1993) 2.56
Plasmodium falciparum maturation abolishes physiologic red cell deformability. Science (1984) 2.51
Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest (1971) 2.49
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism. J Clin Invest (1978) 2.48
Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med (1975) 2.46
Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med (1974) 2.39
Antimicrobial synergism--an elusive concept. J Infect Dis (1979) 2.39
Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother (1972) 2.36
Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother (1987) 2.35
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 2.29
Antimalarials increase vesicle pH in Plasmodium falciparum. J Cell Biol (1985) 2.27
Recovery of resistance (R) factors from a drug-free community. Lancet (1969) 2.26
Drug therapy: The newer cephalosporins. N Engl J Med (1976) 2.20
SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother (2000) 2.15
Simplified storage and retrieval of stock cultures. Appl Microbiol (1972) 2.12
Studies on the mechanism of intrinsic resistance to beta-lactam antibiotics in group D streptococci. J Gen Microbiol (1983) 2.10
Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation (1974) 2.08
Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci. Antimicrob Agents Chemother (Bethesda) (1970) 2.07
Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria. Am J Med (1977) 2.07
Use of the Rapid STREP system for identification of viridans streptococcal species. J Clin Microbiol (1983) 2.02
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
Identification of viridans streptococci isolated from clinical specimens. J Clin Microbiol (1982) 1.98
Carmine as a source of nosocomial salmonellosis. N Engl J Med (1967) 1.98
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob Agents Chemother (1997) 1.96
Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother (1991) 1.94
Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother (1983) 1.93
A nutrient-permeable channel on the intraerythrocytic malaria parasite. Nature (1993) 1.91
Genitourinary tuberculosis. Clinical features in a general hospital population. Am J Med (1977) 1.91
Plasmid-mediated resistance to antibiotic synergism in enterococci. J Clin Invest (1978) 1.90
The so-called "Paracolon" bacteria. A bacteriologic and clinical reappraisal. Am J Med (1967) 1.88
Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin. Antimicrob Agents Chemother (1974) 1.86
In vitro activities of two glycylcyclines against gram-positive bacteria. Antimicrob Agents Chemother (1994) 1.82
Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob Agents Chemother (1986) 1.77
Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1991) 1.75
Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns. Antimicrob Agents Chemother (1983) 1.74
Enterococcal infections in patients treated with moxalactam. Rev Infect Dis (1983) 1.72
Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob Agents Chemother (1990) 1.71
Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin. Antimicrob Agents Chemother (1981) 1.67